Moleculin Biotech (MBRX) Retained Earnings (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Retained Earnings of $10000.0 for Q4 2025, up 100.01% year-over-year from $4999.9 in Q4 2024, and up 100.0% quarter-over-quarter from -$221.6 million in Q3 2025.
Moleculin Biotech (MBRX) Retained Earnings (2015 - 2026) Analysis & Trends
Moleculin Biotech's Retained Earnings history runs 11 years deep, the most recent figure standing at $10000.0 for Q4 2025.
- In Q4 2025, Retained Earnings rose 100.01% year-over-year to $10000.0; the TTM figure through Dec 2025 stood at $10000.0 (up 100.01% YoY), while the FY2025 annual figure was $10000.0, up 100.01% from the prior year.
- Retained Earnings for Q4 2025 stood at $10000.0, up from -$221.6 million in the prior quarter.
- The five-year high for Retained Earnings was $10000.0 in Q4 2025, with the low at -$221.6 million in Q3 2025.
- The 5-year median for Retained Earnings is -$112.7 million (2023), against an average of -$115.4 million.
- The sharpest annual moves came in 2021 and 2025: Retained Earnings tumbled 50.49% in 2021, then jumped 100.01% in 2025.
- Moleculin Biotech's Retained Earnings stood at -$72.8 million in 2021, then slumped by 39.86% to -$101.8 million in 2022, then decreased by 29.23% to -$131.6 million in 2023, then plunged by 31.03% to -$172.4 million in 2024, then surged by 100.01% to $10000.0 in 2025.
- Business Quant data shows MBRX's Retained Earnings at $10000.0 in Q4 2025, -$221.6 million in Q3 2025, and -$196.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | -226.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -226.50 Mn |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | -221.56 Mn |
| Jun 30, 2025 | -196.16 Mn |
| Mar 31, 2025 | -178.35 Mn |
| Dec 31, 2024 | -172.44 Mn |
| Sep 30, 2024 | -151.50 Mn |
| Jun 30, 2024 | -140.89 Mn |
| Mar 31, 2024 | -136.57 Mn |
| Dec 31, 2023 | -131.60 Mn |
| Sep 30, 2023 | -121.34 Mn |
| Jun 30, 2023 | -115.73 Mn |
| Mar 31, 2023 | -109.75 Mn |
| Dec 31, 2022 | -101.84 Mn |
| Sep 30, 2022 | -95.10 Mn |
| Jun 30, 2022 | -86.45 Mn |
| Mar 31, 2022 | -79.68 Mn |
| Dec 31, 2021 | -72.81 Mn |
| Sep 30, 2021 | -69.98 Mn |
| Jun 30, 2021 | -65.60 Mn |